MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Kodu・Aktsiate loetelu・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Suletud

SektorTervishoid

23.6 -0.38

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

23.35

Max

24.13

Põhinäitajad
By Trading Economics
Sissetulek	10M 17M
Müük	30M 130M
Aktsiakasum	0.13
Kasumimarginaal	13.432
Töötajad	354
EBITDA	11M 22M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+45.28% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-577M 2.6B
Eelmine avamishind	23.98
Eelmine sulgemishind	23.6

Uudiste sentiment

By Acuity

50%

170 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

12.42 / 14.93 Toetus ja vastupanu

Arcutis Biotherapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. apr 2026, 23:17 UTC

Tulu

Samsung Forecasts Record First-Quarter Operating Profit

6. apr 2026, 23:00 UTC

Kuumad aktsiad

Stocks to Watch: Health Insurers, Mawson, Owlet

6. apr 2026, 22:13 UTC

Suurimad hinnamuutused turgudel

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6. apr 2026, 21:46 UTC

Omandamised, ülevõtmised, äriostud

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6. apr 2026, 17:09 UTC

Suurimad hinnamuutused turgudel

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6. apr 2026, 16:56 UTC

Uudisväärsed sündmused

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6. apr 2026, 14:47 UTC

Suurimad hinnamuutused turgudel

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6. apr 2026, 23:58 UTC

Market Talk

Uudisväärsed sündmused

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6. apr 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6. apr 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6. apr 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6. apr 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6. apr 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6. apr 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6. apr 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. apr 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. apr 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6. apr 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6. apr 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6. apr 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6. apr 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6. apr 2026, 18:36 UTC

Omandamised, ülevõtmised, äriostud

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. apr 2026, 17:59 UTC

Market Talk

Uudisväärsed sündmused

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6. apr 2026, 17:13 UTC

Omandamised, ülevõtmised, äriostud

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. apr 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6. apr 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. apr 2026, 14:59 UTC

Tulu

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Võrdlus sarnastega

Hinnamuutus

Arcutis Biotherapeutics Inc Prognoos

Hinnasiht

By TipRanks

45.28% tõus

12 kuu keskmine prognoos

Keskmine 34.33 USD 45.28%

Kõrge 36 USD

Madal 31 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Arcutis Biotherapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Arcutis Biotherapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

12.42 / 14.93Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

170 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.